Compare NCA & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCA | CMPS |
|---|---|---|
| Founded | 1987 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.0M | 1.9B |
| IPO Year | 1995 | 2020 |
| Metric | NCA | CMPS |
|---|---|---|
| Price | $8.91 | $14.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.38 |
| AVG Volume (30 Days) | 60.7K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.59 | $4.82 |
| 52 Week High | $9.80 | $15.87 |
| Indicator | NCA | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 23.47 | 54.42 |
| Support Level | $8.80 | $13.07 |
| Resistance Level | $9.49 | $14.87 |
| Average True Range (ATR) | 0.12 | 0.78 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 4.59 | 44.99 |
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.